USP and Public Policy

usp public policy
Left
usp public policy

Refine Your Search

All Results
USP Comments to FDA RFI on Biosimilar Product Development Guidance (2024)
USP Comments to FDA RFI on Biosimilar Product Development Guidance submitted October 23, 2024. Learn More
USP Comments to Congressional RFI on policy solutions to secure and enhance domestic medical supply chains (2024)
USP Comments to Congressional Request for Information (RFI) regarding policy solutions to secure and enhance domestic medical supply chains. Submitted on October 4, 2024.  Learn More
USP Comment Letter to FDA on Advanced Manufacturing Technologies Designation Program; Draft Guidance for Industry
USP Comment Letter to FDA on Advanced Manufacturing Technologies Designation Program; Draft Guidance for Industry. Submitted on March 12, 2024. Learn More
USP Comment Letter: Submitted to DEA on Schedules of Controlled Substances: Rescheduling of Marijuana
USP Comment Letter Submitted to DEA on July 24, 2024 regarding schedules of Controlled Substances: Rescheduling of Marijuana (Docket No. DEA-2024-0059; A.G. Order No. 5931-2024). Learn More
USP Comment Letter: Submitted to Congress on CURES 2.0 Request for Information (August 2024)
USP Comment Letter submitted to Congress on CURES 2.0 Request for Information. Submitted on August 2, 2024 Learn More
USP Comment Letter: Submitted to DEA for Schedules of Controlled Substances: Rescheduling of Marijuana (July 2024)
USP Comment Letter: Submitted to DEA for Schedules of Controlled Substances: Rescheduling of Marijuana; (Docket No. DEA-2024-0059; A.G. Order No. 5931-2024). Submitted on July 22, 2024. Learn More
USP Comments on the Senate Finance Committee’s Legislative Draft "Drug Shortage Prevention and Mitigation Act” (2024)
Learn More
USP Comment Letter to Office of the National Coordinator for Health Information Technology (ONC) regarding 2024-2030 Federal Health IT Strategic Plan (2024)
Learn More
USP Comment Letter: Submitted to Office of the United States Trade Representative on Comments on Promoting Supply Chain Resilience (USTR-20240002)
USP Comment Letter: Submitted to Office of the United States Trade Representative on Comments on Promoting Supply Chain Resilience (USTR-20240002) (2024) Learn More
USP Comment Letter: Submitted to FDA on NDI Draft Guidance (2011)
The USP submits comments to the Draft Guidance for Industry; Dietary Supplements: New Dietary Ingredient Notifications and Related Issues (“Guidance”) published by the Food and Drug Administration (… Learn More

Document Classification

Topics